Close Menu

ChIP-seq

In PNAS this week: possible treatment targets in KRAS-mutated lung cancer, transcriptional analysis of mouse models lacking a p53 inhibitor, and more.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

In more than a dozen new papers, ENCODE researchers reported on analyses of the human and mouse genomes, using new data types and additional tissues.

Transcription factor reprogramming during prostate cancer metastases appears to involve epigenetic changes that resemble those at play during prostate development, new research finds.

In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.

Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.

Researchers used genomic approaches to delve into the cleft lip and palate-related functions of a transcription factor called p63, identifying key enhancer and chromatin interactions.

A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.